Cyclophosphamide, as a cytotoxic agent in blood deficiency animal models, damages peripheral blood cells and bone marrow cells, with particularly prominent injury to leukocytes. Acetylphenylhydrazine induces damage to peripheral erythrocytes with slow yet long-lasting effects. The combined administration of cyclophosphamide and acetylphenylhydrazine causes injury to the immune and circulatory systems of the body. This disease model is commonly established by the combined use of acetylphenylhydrazine and cyclophosphamide. The combined intervention markedly reduces the levels of erythrocytes, leukocytes, platelets and hemoglobin in model animals, and constructs a blood deficiency state through dual pathogenic pathways. This modeling method presents a high survival rate of experimental animals and a relatively long duration of blood deficiency, which is suitable for subsequent experimental research.

SPF-grade KM mice (6 weeks old, regardless of gender)
Modeling method: Acetylphenylhydrazine was injected subcutaneously, followed by intraperitoneal injection of cyclophosphamide for 4 consecutive days to successfully establish the blood deficiency syndrome model.
Positive drug: Erythropoietin
Evaluation index: Routine blood test